CRISPR Therapeutics AG (CRSP)
Daily ERM3 factor decomposition: how much of CRSP's variance is explained by the market, its sector, and its subsector — and the ETF notionals that would neutralize each layer.
- Price
- $49.39
- Market cap
- $4.8B
- 23-day vol
- 47.2%
- Sector proxy
- XLV
- Subsector proxy
- XBI
Risk DNA
42% of CRSP's variance is systematic (explainable by market, sector, and subsector factors); the rest is stock-specific.
CRSP carries 58% stock-specific risk against a peer average of 83% — less of what happens here is specific to this name than is typical for its cohort.
ETF hedge ratios
Dollars of ETF to short per $1 of CRSP held — executable hedge weights, not regression betas. L1 hedges market only; L3 adds sector and subsector layers.
| Level | Market (SPY) | Sector (XLV) | Subsector (XBI) | Explained risk |
|---|---|---|---|---|
| L1 | $-2.01 | — | — | 15.5% |
| L2 | $-1.79 | $-0.89 | — | 21.8% |
| L3 | $-0.79 | $-0.27 | $-1.07 | 42.1% |
Data as of October 24, 2026. Updated daily from the ERM3 pipeline.
13F filers holding CRSP
From the most recent quarterly 13F filings in our tracked filer universe, largest reported position first.
Browse every tracked 13F filer.
Go deeper on CRSP
Ask the AI risk analyst for CRSP's full history, peer comparison, or how it changes your portfolio's risk.